HPV testing for cervical cancer screening in Croatia

被引:0
作者
Grce, Magdalena
Grahovac, Blazenka
Rukavina, Tomislav
Vrdoljak-Mozetic, Danijela
Glavas-Obrovac, Ljubica
Kaliterna, Vanja
Zele-Starcevic, Lidija
机构
[1] Rudjer Boskovic Inst, Div Mol Med, HR-10002 Zagreb, Croatia
[2] Rijeka Univ, Sch Med, Dept Pathol, Rijeka, Croatia
[3] Inst Publ Hlth, Dept Microbiol, Rijeka, Croatia
[4] Univ Rijeka, Fac Med, Dept Microbiol & Parasitol, Rijeka, Croatia
[5] Univ Hosp Ctr Rijeka, Dept Obstet & Gynecol, Dept Gynecol Cytol, Rijeka, Croatia
[6] Clin Hosp Osijek, Dept Nucl Med, Osijek, Croatia
[7] Univ Osijek, Sch Med Osijek, Dept Clin Chem & Biochem, Osijek, Croatia
[8] Publ Hlth Teaching Inst Split & Dalmatian Cty, Dept Med Microbiol & Parasitol, Split, Croatia
[9] Univ Zagreb, Dept Med & Mol Microbiol, Clin Hosp Ctr, Zagreb, Croatia
关键词
cervical cancer; human papillomavirus testing; screening programme; quality assessment;
D O I
暂无
中图分类号
Q98 [人类学];
学科分类号
030303 ;
摘要
Opportunistic screening based on the Pap smear has been undertaken in Croatia since 1953. However, cervical cancer remains an important health problem in Croatia when compared to European countries with organised screening programmes. In Croatia, in addition to screening based on well established cytology, Human papillomavirus (HPV) testing is widely used as secondary test as a triage to borderline cytology and as a follow-up after treatment of severe cervical lesions. Many different approaches for HPV testing arose in Croatia over the last decade depending on the needs of each medical institution involved. Presently, there is an urgent need for better networking between the laboratories, the implementation of quality assessment and the adaptation of a uniform system of referring to and reporting of HPV testing. In conclusion, the best possible organisation for HPV testing would be essential for implementation of HPV testing as primary screening test in Croatia, an thus ultimately and hopefully, the more successful cervical cancer control.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 26 条
[1]  
[Anonymous], 2005, Cervix Cancer Screening
[2]  
[Anonymous], 2003, GYNAECOL PERINATOL
[3]   European Code Against Cancer and scientific justification: third version (2003) [J].
Boyle, P ;
Autier, P ;
Bartelink, H ;
Baselga, J ;
Boffetta, P ;
Burn, J ;
Burns, HJG ;
Christensen, L ;
Denis, L ;
Dicato, M ;
Diehl, V ;
Doll, R ;
Franceschi, S ;
Gillis, CR ;
Gray, N ;
Griciute, L ;
Hackshaw, A ;
Kasler, M ;
Kogevinas, M ;
Kvinnsland, S ;
La Vecchia, C ;
Levi, F ;
McVie, JG ;
Maisonneuve, P ;
Martin-Moreno, JM ;
Bishop, JN ;
Oleari, F ;
Perrin, P ;
Quinn, M ;
Richards, M ;
Ringborg, U ;
Scully, C ;
Siracka, E ;
Storm, H ;
Tubiana, M ;
Tursz, T ;
Veronesi, U ;
Wald, N ;
Weber, W ;
Zaridze, DG ;
Zatonski, W ;
zur Hausen, H .
ANNALS OF ONCOLOGY, 2003, 14 (07) :973-1005
[4]   Standardization and quality control of PCR analyses [J].
Burkardt, HJ .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (02) :87-91
[5]   HPV DNA testing in cervical cancer screening: From evidence to policies [J].
Cox, Tom ;
Cuzick, Jack .
GYNECOLOGIC ONCOLOGY, 2006, 103 (01) :8-11
[6]  
*CROAT NAT CANC RE, 2001, B CROAT NAT CANC REG, V24
[7]   Overview of the European and North American studies on HPV testing in primary cervical cancer screening [J].
Cuzick, Jack ;
Clavel, Christine ;
Petry, Karl-Ulrich ;
Meijer, Chris J. L. M. ;
Hoyer, Heike ;
Ratnam, Samuel ;
Szarewski, Anne ;
Birembaut, Philippe ;
Kulasingam, Shalini ;
Sasieni, Peter ;
Iftner, Thomas .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) :1095-1101
[8]  
DAVIES P, 2007, IN PRESS COLL ANT S2, V31
[9]  
FERLAY J, 2004, GLOBOCAN 2002
[10]   Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more [J].
Goldie, SJ ;
Kim, JJ ;
Wright, TC .
OBSTETRICS AND GYNECOLOGY, 2004, 103 (04) :619-631